Trials Focused on ctDNA in Colorectal Cancer
An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.
Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression
A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.
T-DXd in Patients With HER2+ Metastatic Colorectal Cancer
A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.
Patient Profile: A 40-Year-Old Woman With Colorectal Cancer
Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.
Metastatic CRC: Role of ctDNA in Treatment Selection
Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.
PARADIGM Trial: Recent Data on EGFR-Targeting Therapy for mCRC
Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.
Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression
Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.
MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer
Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.
Treatment Landscape for HER2+ Metastatic Colorectal Cancer
An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.
Overview of HER2+ Metastatic Colorectal Cancer
Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.
Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer
A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.
2 Clarke Drive Cranbury, NJ 08512